Janssen Pharmaceutica Nv

Meri De Angelis

Michael Anthony Letavic

Curt A Dvorak

Heather Renee Coate

Brad M Savall

Devin M Swanson

Christine Fang Gelin

Brice M Stenne

Christa C Chrovian

Akinola Soyode-Johnson

Jose Ignacio Andres Gil

Manuel Jesus Alcazar Vaca

Greta Constantia Vanhoof

Peter Jacobus Buijnsters

Frederik Jan Rombouts

Andrés Avelino Trabanco-Suárez

Jérôme Emile Georges Guillemont

Neelakandha S Mani

José Ignacio Andrés-Gil

Jerôme Emile Georges Guillemont

Xiaohu Deng

Jason Christopher Rech

Brett D Allison

Frederik Jan Rita Rombouts

Maarten Vliegen

Peter Jacobus Johannes Antonius Buijnsters

Jessica L Wall

Jimmy T Liang

Antonius Adrianus Hendrikus Petrus Megens

Guy Maurits R Bormans

Xavier Jean Michel Langlois

Greta Constantia Peter Vanhoof

Sofie Jeanne Leopoldine Celen

Antonius Adrianus Megens

Xavier Jean Langlois

Guy Maurits Bormans

Sofie Jeanne Celen

José Ignacio ANDRÉS-Gil

Jerome Emile Guillemont

The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

P2X7 modulators

The present invention is directed to compounds of Formulas (I, IIa and IIb):  The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives

The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention. 

P2X7 modulators and methods of use

Growing community of inventors

Munich, Germany

Meri De Angelis